The current macro environment appears grim, given the uncertainty around the global trade war, along with ongoing ...

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.

The biotech sector has struggled broadly and the massive ... Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to ...

R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth re ...

Not all corners of the market are moving in the same direction this year; 2025 has already delivered a few surprises for ...

The analyst believes Marks’ departure will have a negative impact on the biotech sector, extending beyond ... leadership could weigh on their stock performance. Beyond RBC, analysts at Cantor ...

Evaxion Biotech’s financial performance in Q4 2024 shows marked ... to differentiate it from competitors in the biotech sector. Revenue: $3.3 million, primarily from an MSD license agreement.

Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving breakthroughs in medicine, agriculture, and environmental sustainability. As we look ahead to ...

Omega Funds founder and managing director Otello Stampacchia isn’t afraid to tell it like he sees it.